In vitro identification of the cytochrome P450 isoform responsible for the metabolism of α-dihydroergocryptine

Xenobiotica

Volumn 30, Issue 11, 2000, Pages 1033-1045

  Althaus, M ^a   Retzow, A ^a   Castell, J V ^b   Gomez Lechon M J ^b   Amalou, Z ^c   Rose, T ^c   Appel, K ^c  

^a ALK SCHERAX Arzneimittel GmbH   (Germany)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c Pharmbiodyn GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DIHYDROERGOCRYPTINE;

ARTICLE; BIOTRANSFORMATION; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG METABOLISM; ENZYME ACTIVITY; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER CELL CULTURE; PARKINSON DISEASE; PROTEIN ANALYSIS;

AGED; ANIMALS; BROMOCRIPTINE; CELL LINE; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; CYTOCHROME P-450 ENZYME SYSTEM; DIHYDROERGOTOXINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEPATOCYTES; HUMANS; HYDROXYTESTOSTERONES; LIVER; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MODELS, CHEMICAL; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TIME FACTORS;

EID: 0034492431     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250010002261     Document Type: Article

References (32)

1. Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans
2. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
3. Alpha-dihydroergocryptine in Parkinson's disease: A multicentre randomized double blind parallel group study
4. Gender differences in pharmacokinetics and pharmacodynamics
5. Alpha-dihydroergocryptine in the treatment of de novo Parkinsonian patients: Results of a multicentre, randomized, double blind, placebo-controlled study
6. Hepatic metabolism of diclofenac: Role of human CYP in the minor oxidative pathways
7. Drug biotransformation
8. Metabolism of dihydroergotamine by a cytochrome P-450 similar to that involved in the metabolism of macrolide antibiotics
9. V79 Chinese hamster cells genetically engineered for cytochrome P450 and their use in mutagenicity and metabolism studies
10. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
11. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes
12. Culture of human hepatocytes from small surgical biopsies. Biochemical characterization and comparison with in vivo
13. CYP3A gene expression in human gut epithelium
14. Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries
15. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines
16. Dopamine receptor profile of co-dergocrine (Hydergine-) and its components
17. -3H(N)] in rat and human hepatocyte cultures and rat, monkey, and human microsomes
18. Elucidation of the structure and receptor binding studies of the major primary metabolite of dihydroergotamine in man
19. Fate and disposition of bromocriptine in animals and man. I: Structure and elucidation of the metabolites
20. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes
21. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine
22. High affinity of ergopeptides for cytochrome P450 3A
23. Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens
24. Highly efficient establishment of immortalized cells from adult human liver
25. Genetically engineered V79 Chinese hamster cell expression of purified cytochrome P-450IIBI monooxygenase activity
26. Stable expression of human P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives
27. Quantitative RT-PCR measurement of human cytochrome P-450 application to drug induction studies
28. 3H-α-dihydroergocryptine mesylate
29. Gender-related differences in pharmacokinetics and their clinical significance
30. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen